End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.08 PLN | -11.11% | -.--% | -.--% |
2023 | Remedis SA Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
2023 | Remedis SA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 | CI |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 5.064 | 1.899 | 2.026 | 10 | 7.596 | 3.766 |
Enterprise Value (EV) 1 | 12.91 | 9.744 | 8.786 | 16.22 | 13.36 | 10.49 |
P/E ratio | -8.94 x | -1.72 x | 10.7 x | -7.05 x | -10.2 x | -1.41 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 6.09 x | 3.88 x | 2.74 x | -84.1 x | -25.5 x | -5.3 x |
EV / Revenue | 15.5 x | 19.9 x | 11.9 x | -136 x | -44.8 x | -14.8 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | 0.81 x | 0.37 x | 0.38 x | 2.56 x | 2.4 x | 7.56 x |
Nbr of stocks (in thousands) | 63,300 | 63,300 | 63,300 | 63,300 | 63,300 | 63,300 |
Reference price 2 | 0.0800 | 0.0300 | 0.0320 | 0.1580 | 0.1200 | 0.0595 |
Announcement Date | 3/20/18 | 3/14/19 | 3/20/20 | 3/22/21 | 3/21/22 | 5/31/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 0.8312 | 0.4893 | 0.7404 | -0.119 | -0.2981 | -0.7107 |
EBITDA | - | - | - | - | - | - |
EBIT | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.5497 | -1.066 | 0.3491 | -1.52 | -0.7894 | -2.67 |
Net income 1 | -0.5665 | -1.104 | 0.1895 | -1.42 | -0.7434 | -2.67 |
Net margin | -68.16% | -225.56% | 25.59% | 1,193.27% | 249.37% | 375.66% |
EPS 2 | -0.008950 | -0.0174 | 0.002993 | -0.0224 | -0.0117 | -0.0422 |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/20/18 | 3/14/19 | 3/20/20 | 3/22/21 | 3/21/22 | 5/31/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 7.84 | 7.85 | 6.76 | 6.21 | 5.77 | 6.72 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | -8.68% | -19.4% | 3.62% | -30.7% | -21% | -146% |
ROA (Net income/ Total Assets) | -3.78% | -7.92% | 1.45% | -11.7% | -6.54% | -26.1% |
Assets 1 | 15 | 13.94 | 13.04 | 12.12 | 11.37 | 10.22 |
Book Value Per Share 2 | 0.1000 | 0.0800 | 0.0800 | 0.0600 | 0.0500 | 0.0100 |
Cash Flow per Share 2 | 0 | 0 | 0 | 0.0100 | 0.0200 | 0 |
Capex | - | - | 0 | 0 | - | - |
Capex / Sales | - | - | 0.25% | -1.69% | - | - |
Announcement Date | 3/20/18 | 3/14/19 | 3/20/20 | 3/22/21 | 3/21/22 | 5/31/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-.--% | 1.27M | |
+74.14% | 27.17B | |
+26.97% | 19.11B | |
+23.82% | 15.67B | |
+10.48% | 9.38B | |
-20.73% | 7.61B | |
+16.60% | 7.04B | |
+73.69% | 5.82B | |
+0.18% | 4.98B | |
+82.35% | 4.96B |
- Stock Market
- Equities
- REM Stock
- Financials Remedis SA